Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20609287 | 0.85 | MMP8 (0.31) | MMP8CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL18068808 | 0.84 | MMP8 (0.36) | MMP8CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10148470 | 0.83 | CA1 (0.35) | MMP8CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL786077 | 0.83 | CYP3A4 (0.33) | MMP8CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL25468235 | 0.82 | MMP8 (0.32) | MMP8CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL17848845 | 0.82 | HMGCR (0.37) | MMP8CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL12390095 | 0.81 | MMP8 (0.39) | MMP8CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL17860868 | 0.80 | CYP3A4 (0.32) | CYP3A4CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL10304138 | 0.80 | LMNA (0.37) | CYP3A4CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL12934757 | 0.80 | CYP3A4 (0.32) | CYP3A4CYP1A2CYP2D6CYP2C9NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | MMP8 786/4885CYP3A4 3756/4885CYP1A2 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.